Nightstar Therapeutics Plc – American Depositary S (NASDAQ:NITE) Shorts Increased By 10.38% As Of Apr 18, 2019

It was registered an increase on Nightstar Therapeutics Plc – American Depositary S (NASDAQ:NITE)’s short interest with 10.38%. FINRA announced short interest of NITE’s total 582,700 shares. That’s 10.38% up from 527,900 shares. Nightstar Therapeutics Plc – American Depositary S (NASDAQ:NITE) has 35,000 shares average volume. It’ll cost 17 days for NITE to recover its previous position. Nightstar Therapeutics Plc – American Depositary S’s short interest float is 3.13%.

Ticker’s shares touched $25.5 during the last trading session after 0.08% change.Nightstar Therapeutics plc has volume of 142,232 shares. Since April 18, 2018 NITE has risen 100.32% and is uptrending. The stock outperformed the S&P 500 by 95.95%.

Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases.The company has $855.17 million market cap. The companyÂ’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.Last it reported negative earnings. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy.

Nightstar Therapeutics plc (NASDAQ:NITE) Ratings Coverage

Total analysts of 6 have positions in Nightstar Therapeutics (NASDAQ:NITE) as follows: 0 rated it a “Buy”, 0 with “Sell” and 6 with “Hold”. The positive are 0. Since February 23, 2019 according to StockzIntelligence Inc Nightstar Therapeutics has 8 analyst reports. On Tuesday, March 5 the company was downgraded by Leerink Swann. On Monday, March 4 the company was downgraded by Cantor Fitzgerald. On Monday, March 25 the rating was downgraded by Barclays Capital to “Equal-Weight”. On Tuesday, March 5 the firm has “Neutral” rating given by Mizuho. On Tuesday, March 5 the firm has “Market Perform” rating by BMO Capital Markets given. On Tuesday, March 5 UBS downgraded the shares of NITE in report to “Neutral” rating.

For more Nightstar Therapeutics plc (NASDAQ:NITE) news posted recently go to: Streetinsider.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Nightstar Therapeutics (NITE) Announcement of Expiry of HSR Waiting Period and Satisfaction of Antitrust Condition – StreetInsider.com” posted on April 16, 2019, “Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results – GlobeNewswire” on November 13, 2018, “Nightstar Announces Pricing of Public Offering Nasdaq:NITE – GlobeNewswire” with a publish date: September 27, 2018, “Nightstar (NITE) Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Nightstar Therapeutics Plc is Fair to Nightstar Shareholders – NITE – GlobeNewswire” and the last “Nightstar Therapeutics to Participate in Multiple Conferences in November – GlobeNewswire” with publication date: November 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.